Table 3. Clinical studies about the use of thiazides and the risk of skin cancers.
| Author, year | Study design | Cancer type | Drug | Results |
|---|---|---|---|---|
| Jensen, 2008 | Case-control | SCC | HCTZ + amiloride (>5 years) | IRR 1.79 (1.45-2.21) |
| Ruiter, 2010 | Cohort | BCC | Thiazides | HR 1.0 (0.95-1.05) |
| Friedman, 2012 | Case-control | SCC Lip cancer | HCTZ | OR 4.22 (2.82-6.31) |
| De Vries, 2012 | Case-control | SCC | Thiazides | OR 1.66 (1.16-2.37) |
| Robinson, 2013 | Case-control | SCC | Thiazides | OR 1.3 (0.7-2.4) |
| Schmidt, 2015 | Case-control | SCC | Thiazides + potassium sparing agents | OR 2.68 (2.24-3.21) |
| Pottergard, 2017 | Caso-controle | SCC CA lábio | HCTZ ≥ 25.000 mg | OR 3.9 (3.0-4.9) |
| Thiazides | ||||
| Nardone, 2017 | Coorte | BCC/SCC/MM | Thiazides | BCC: OR 2.11 1.60-2.79) |
| SCC: OR 4.11 (2.66-6.35) | ||||
| MM: OR 1.82 (1.01-3.82) | ||||
| Pedersen, 2018 | Case-control | NMSC | HCTZ >50.000mg | BCC: OR 1.29 (1.23-1.35) |
| (BCC/SCC) | (cumulative dose) | SCC: OR 3.98 (3.68-4.31) | ||
| Su, 2018 | Cohort | SCC | Tiazídicos Thiazides | HR 1.09 (0.99-1.19) |
SCC: squamous cell carcinoma; IRR: incidence rate ratio; OR: odds ratio (confidence interval); NMSC: nonmelanoma skin cancer; BCC: basal cell carcinoma; HR: hazard ratio; HCTZ: hydrochlorothiazide; MM: malignant melanoma.